Policy Developments - The National Healthcare Security Administration (NHSA) announced that by the end of 2025, all coordinated areas in the country must implement instant settlement for medical insurance funds [2] - By the end of 2026, instant settlement funds should account for over 80% of the local medical insurance fund's monthly settlement funds, covering various medical expenses [2] Industry Developments - Jiangxi Province is promoting the development of modern seed industry for traditional Chinese medicine, focusing on the protection of medicinal material resources and the establishment of breeding bases [3] - The company Jiuzhoutong received approval for the market launch of the chemical raw material drug, Glycopyrrolate, which will enhance its product line and market competitiveness [5] - Sichuan Shuangma's subsidiary obtained approval for the chemical raw material drug, Leuprolide Acetate, further strengthening its competitive advantage in the domestic raw material drug sector [6] Financial Reports - Guobang Pharmaceutical reported a 23.17% year-on-year increase in net profit for Q3, despite a 5.39% decline in revenue [8] Investment Activities - OxTium Technology completed several million yuan in angel+ round financing, led by Sequoia China Seed Fund [11] Clinical Research - Eli Lilly announced positive results from two Phase 3 clinical trials for orforglipron, showing significant improvements in blood sugar control and weight loss for type 2 diabetes patients [14] Shareholder Actions - Kangtai Medical announced that major shareholder Wang Guili reduced her holdings by 4.24 million shares, decreasing her ownership to 8.95% [17]

Core Viewpoint - Sichuan Shuangma announced that its subsidiary, Hubei Jianxiang Biopharmaceutical Co., Ltd., has received the approval notice for the listing application of Acetyl-L-carnitine from the National Medical Products Administration [1] Group 1 - The approval is significant for the company as it expands its product offerings in the pharmaceutical sector [1] - The approval indicates a positive regulatory environment for the company's operations and potential growth in the biopharmaceutical market [1]

Group 1 - Dingjide's subsidiary has successfully launched the industrial production of POE materials, achieving stable production of qualified products [1] - Xinhua Insurance reported a 19% year-on-year increase in original insurance premium income for the first three quarters, totaling 172.705 billion yuan [1] - Chunfeng Power achieved a 30.89% year-on-year increase in net profit for the first three quarters, with total revenue reaching 14.15 billion yuan [1][2] Group 2 - Guangsheng Nonferrous expects a net profit of 100 million to 130 million yuan for the first three quarters, marking a turnaround from losses [1] - Aobi Zhongguang anticipates a net profit of approximately 108 million yuan for the first three quarters, with revenue growth of 103.5% [1] - Guobang Pharmaceutical reported a 15.78% year-on-year increase in net profit for the first three quarters, totaling 6.7 billion yuan [1] Group 3 - Zhujiang Co. manages 428 projects with a signed construction area of approximately 50.9853 million square meters as of September 2025 [1] - Kecuan Technology has terminated its application for issuing convertible bonds, considering its development plan and actual situation [1] - Guoxin Securities has received approval to register 15 billion yuan in short-term corporate bonds [1] Group 4 - Aihua Pharmaceutical's clinical trial for a pediatric cough syrup has been approved by the National Medical Products Administration [1] - Xinjiang Jiaojian signed new construction contracts worth 1.413 billion yuan in the third quarter [1] - Sichuan Shuangma's subsidiary has received approval for the listing of a raw material drug used in treating various diseases [1] Group 5 - Gansu Energy's 1,000 MW coal-fired unit has officially commenced commercial operation [1] - Zhejiang Energy reported a 4.68% year-on-year increase in power generation for the first three quarters, totaling 135.234 billion kWh [1] - Tiandi Source's contract sales amount for the first nine months decreased by 16.18% to 3.085 billion yuan [1] Group 6 - Biological Shares' subsidiary has obtained a new veterinary drug registration certificate for a vaccine [1] - Jintong Co. reported a 4.03% year-on-year increase in net profit for the first three quarters, totaling 2.283 billion yuan [1] - Rihua Technology plans to invest 800 million yuan in a new project for industrial ray detection equipment [1] Group 7 - Zhongtian Technology has won multiple marine project bids totaling approximately 1.788 billion yuan [1] - Qingsong Co. has completed the disposal of a 148-acre industrial park project, transferring it for 163 million yuan [1] - Tongyuan Petroleum has successfully bid for a $126 million oil and gas service project in Algeria [1] Group 8 - Hengmingda's chairman proposed a share buyback plan of 200 million to 400 million yuan [1] - Deyi Cultural plans to reduce its holdings by up to 1% of the company's shares [1] - Feirongda's major shareholder plans to reduce its holdings by up to 2.36% of the company's shares [1] Group 9 - Mankun Technology plans to issue convertible bonds to raise no more than 760 million yuan for high-end PCB production and digital upgrades [1] - Sanlian Forging's shareholder plans to reduce its holdings by up to 3% of the company's shares [1] - Huagong Technology intends to jointly establish a venture capital fund with a target size of 500 million yuan [1] Group 10 - Shida Shenghua expects a net loss of 49 million to 75 million yuan for the first three quarters [1] - Huichuangda's major shareholder plans to reduce its holdings by up to 0.65% of the company's shares [1] - Yuxin Electronics reported a 60.21% year-on-year increase in net profit for the first three quarters, totaling 73.3941 million yuan [1] Group 11 - Yiwei Communication expects a 50% to 55% decline in net profit for the first three quarters [1] - Lio Co. plans to reduce its repurchased shares by up to 135 million shares [1] - Sichuan Shuangma's subsidiary has received approval for a new drug registration [1]

Core Viewpoint - Sichuan Shuangma announced that its subsidiary Hubei Jianxiang Biopharmaceutical Co., Ltd. has recently received the approval notice for the listing application of Acetate Leuprolide from the National Medical Products Administration [1] Company Summary - Hubei Jianxiang Biopharmaceutical Co., Ltd. is now authorized to market Acetate Leuprolide, a GnRH agonist, which effectively suppresses the secretion of gonadotropins when administered continuously at therapeutic doses [1] - The approved indications for Acetate Leuprolide in China include treatment for endometriosis, uterine fibroids, prostate cancer, estrogen receptor-positive premenopausal breast cancer, and central precocious puberty [1]

Core Viewpoint - Sichuan Shuangma (000935) announced that its subsidiary, Hubei Jianxiang Biopharmaceutical Co., Ltd., has recently received the approval notice for the listing application of Acetate Leuprolide from the National Medical Products Administration [1] Group 1: Company Developments - The approval pertains to Acetate Leuprolide, a Gonadotropin-Releasing Hormone (GnRH) agonist, which effectively suppresses the secretion of gonadotropins when administered at therapeutic doses [1] - The drug is currently approved in China for the treatment of endometriosis, uterine fibroids, prostate cancer, estrogen receptor-positive premenopausal breast cancer, and central precocious puberty [1]

格隆汇10月16日丨四川双马(000935.SZ)公布，控股子公司湖北健翔生物制药有限公司（简称"湖北健 翔"）于近期获得国家药品监督管理局签发的醋酸亮丙瑞林《化学原料药上市申请批准通知书》。醋酸 亮丙瑞林是一种促性腺激素释放激素（GnRH）激动剂，治疗剂量下持续给药可有效抑制促性腺激素的 分泌。目前国内获批用于子宫内膜异位症、子宫肌瘤、前列腺癌、雌激素受体阳性的绝经前乳腺癌、中 枢性性早熟的治疗。 ...

四川双马(000935.SZ)公告称，公司控股子公司湖北健翔生物制药有限公司近日获得国家药品监督管理 局签发的醋酸亮丙瑞林《化学原料药上市申请批准通知书》。该原料药已符合国家相关原料药审评技术 要求，可在国内市场进行生产销售，进一步丰富了公司产品线，强化了公司在国内原料药细分领域的竞 争优势。但需注意医药产业特点及市场环境等因素影响，存在不确定性。 ...

四川双马（000935）(000935.SZ)公告，公司控股子公司湖北健翔生物制药有限公司(简称"湖北健翔")于 近期获得国家药品监督管理局签发的醋酸亮丙瑞林《化学原料药上市申请批准通知书》。 公告显示，醋酸亮丙瑞林是一种促性腺激素释放激素(GnRH)激动剂，治疗剂量下持续给药可有效抑制 促性腺激素的分泌。目前国内获批用于子宫内膜异位症、子宫肌瘤、前列腺癌、雌激素受体阳性的绝经 前乳腺癌、中枢性性早熟的治疗。 ...

智通财经APP讯，四川双马(000935.SZ)公告，公司控股子公司湖北健翔生物制药有限公司(简称"湖北健 翔")于近期获得国家药品监督管理局签发的醋酸亮丙瑞林《化学原料药上市申请批准通知书》。 公告显示，醋酸亮丙瑞林是一种促性腺激素释放激素(GnRH)激动剂，治疗剂量下持续给药可有效抑制 促性腺激素的分泌。目前国内获批用于子宫内膜异位症、子宫肌瘤、前列腺癌、雌激素受体阳性的绝经 前乳腺癌、中枢性性早熟的治疗。 ...

证券代码：000935 证券简称：四川双马 公告编号：2025-45 四川和谐双马股份有限公司 关于控股子公司湖北健翔 获得化学原料药上市申请批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 四川和谐双马股份有限公司（简称"公司"）控股子公司湖北健翔生物制药 有限公司（简称"湖北健翔"）于近期获得国家药品监督管理局签发的醋酸亮丙 瑞林《化学原料药上市申请批准通知书》。现将相关情况公告如下： 一、本次获得化学原料药上市申请批准通知书的具体情况 1、化学原料药名称 （1）通用名称: 醋酸亮丙瑞林 （2）英文名/拉丁名: Leuprorelin Acetate 2、登记号: Y20240000206 3、受理号: CYHS2460227 4、包装规格：50g/瓶/袋 5、申请事项：境内生产化学原料药上市申请 6、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执 行。 7、生产企业： （1）名称：湖北健翔生物制药有限公司 （2）地址：湖北咸宁咸安经济开发区绿山路 9 号 二 ...